DK2981624T3 - Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling - Google Patents
Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling Download PDFInfo
- Publication number
- DK2981624T3 DK2981624T3 DK14779403.6T DK14779403T DK2981624T3 DK 2981624 T3 DK2981624 T3 DK 2981624T3 DK 14779403 T DK14779403 T DK 14779403T DK 2981624 T3 DK2981624 T3 DK 2981624T3
- Authority
- DK
- Denmark
- Prior art keywords
- assessment
- prediction
- response
- methods
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000005215 recombination Methods 0.000 title 1
- 230000006798 recombination Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2981624T3 true DK2981624T3 (da) | 2020-03-02 |
Family
ID=51659359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14779403.6T DK2981624T3 (da) | 2013-04-05 | 2014-04-04 | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (https=) |
| EP (2) | EP3693475A1 (https=) |
| JP (5) | JP6625045B2 (https=) |
| AU (3) | AU2014248007B2 (https=) |
| CA (1) | CA2908745C (https=) |
| DK (1) | DK2981624T3 (https=) |
| ES (1) | ES2777228T3 (https=) |
| PT (1) | PT2981624T (https=) |
| WO (1) | WO2014165785A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| EP4563709A3 (en) | 2011-06-17 | 2025-09-03 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| CN107267598B (zh) | 2011-12-21 | 2022-03-25 | 美瑞德生物工程公司 | 用于评估杂合性丢失的方法与材料 |
| WO2013130347A1 (en) | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| ES2658867T3 (es) | 2012-06-07 | 2018-03-12 | Institut Curie | Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| EP3080292B1 (en) | 2013-12-09 | 2022-02-02 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EA201691682A1 (ru) | 2014-02-21 | 2017-02-28 | Эпик Сайенсиз, Инк. | Способы анализирования редких циркулирующих в крови клеток |
| EP4234711B1 (en) | 2014-08-15 | 2025-05-28 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| EP3227464B1 (en) * | 2014-12-05 | 2022-04-20 | Foundation Medicine, Inc. | Multigene analysis of tumor samples |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| GB2553736A (en) | 2015-05-19 | 2018-03-14 | S Sridhar T | Method for identification of a deficient BRCA1 function |
| WO2017079139A1 (en) * | 2015-11-03 | 2017-05-11 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| US20190025312A1 (en) * | 2016-01-06 | 2019-01-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| EP3452937B1 (en) | 2016-05-01 | 2025-10-22 | Genome Research Limited | Method of characterising a dna sample |
| JP7224185B2 (ja) * | 2016-05-01 | 2023-02-17 | ゲノム・リサーチ・リミテッド | Ｄｎａサンプルを特徴付ける方法 |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| SG11202011696TA (en) | 2018-06-11 | 2020-12-30 | Foundation Medicine Inc | Compositions and methods for evaluating genomic alterations |
| JPWO2020137076A1 (ja) * | 2018-12-28 | 2021-11-11 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| AU2020221845A1 (en) | 2019-02-12 | 2021-09-02 | Tempus Ai, Inc. | An integrated machine-learning framework to estimate homologous recombination deficiency |
| AU2020398913A1 (en) | 2019-12-10 | 2022-06-16 | Tempus Ai, Inc. | Systems and methods for predicting homologous recombination deficiency status of a specimen |
| JP2023506084A (ja) * | 2019-12-16 | 2023-02-14 | アジレント・テクノロジーズ・インク | ゲノム瘢痕アッセイ及び関連する方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| US11718869B2 (en) * | 2020-08-12 | 2023-08-08 | Zhenyue Biotechnology Jiangsu Co., Ltd. | Method and kit for determining genome instability based on next generation sequencing (NGS) |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| JP7585015B2 (ja) | 2020-12-04 | 2024-11-18 | 株式会社東芝 | 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法 |
| JP7696647B2 (ja) * | 2021-01-10 | 2025-06-23 | エーシーティー ジェノミックス （アイピー） リミテッド | 相同組換え修復欠損を判定する方法及びそのキット |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| WO2022272310A1 (en) * | 2021-06-25 | 2022-12-29 | Foundation Medicine, Inc. | System and method of classifying homologous repair deficiency |
| CN118369439A (zh) * | 2021-12-08 | 2024-07-19 | 麦利亚德基因公司 | 用于评估乳腺癌亚型中同源重组缺陷的方法和材料 |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| WO2024083971A1 (en) | 2022-10-19 | 2024-04-25 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| DK0612248T3 (da) | 1991-11-15 | 2003-12-08 | Smithkline Beecham Corp | Præparat, der indeholder cisplatin og topotecan som antitumormiddel |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| MXPA03004832A (es) | 2000-12-01 | 2004-05-04 | Guilford Pharm Inc | Compuestos y sus usos. |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| WO2005002508A2 (en) | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| WO2005004805A2 (en) | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| SI1660095T1 (sl) | 2003-07-25 | 2010-05-31 | Cancer Rec Tech Ltd | Triciklični parp inhibitorji |
| CA2535584A1 (en) | 2003-08-13 | 2005-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
| DE602006018299D1 (de) | 2005-06-30 | 2010-12-30 | Bionumerik Pharmaceuticals Inc | Platinanaloga mit monoazolligand |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| DK3327148T3 (da) * | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| ES2704303T3 (es) * | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| WO2013130347A1 (en) * | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
-
2014
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023012488A (ja) | 2023-01-25 |
| AU2022211880B2 (en) | 2025-05-29 |
| US20180030544A1 (en) | 2018-02-01 |
| JP2021036903A (ja) | 2021-03-11 |
| CA2908745C (en) | 2023-03-14 |
| AU2020204028A1 (en) | 2020-07-09 |
| EP2981624B1 (en) | 2019-12-18 |
| PT2981624T (pt) | 2020-03-23 |
| WO2014165785A2 (en) | 2014-10-09 |
| JP7641938B2 (ja) | 2025-03-07 |
| JP2025090619A (ja) | 2025-06-17 |
| AU2022211880A1 (en) | 2022-09-01 |
| JP7522643B2 (ja) | 2024-07-25 |
| JP2019165731A (ja) | 2019-10-03 |
| JP2016523511A (ja) | 2016-08-12 |
| US20140363521A1 (en) | 2014-12-11 |
| US20250223655A1 (en) | 2025-07-10 |
| JP7522539B2 (ja) | 2024-07-25 |
| AU2020204028B2 (en) | 2022-08-18 |
| CA2908745A1 (en) | 2014-10-09 |
| NZ712663A (en) | 2021-07-30 |
| US20210310079A1 (en) | 2021-10-07 |
| EP3693475A1 (en) | 2020-08-12 |
| AU2014248007A1 (en) | 2015-10-15 |
| EP2981624A4 (en) | 2016-11-30 |
| ES2777228T3 (es) | 2020-08-04 |
| JP6625045B2 (ja) | 2019-12-25 |
| AU2014248007B2 (en) | 2020-03-26 |
| EP2981624A2 (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2981624T3 (da) | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling | |
| IL285780A (en) | Tmprss6 irna compositions and methods of use thereof | |
| IL295860B1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| IL283586A (en) | Methods and processes for non-invasive assessment of genetic variations | |
| IL251563B (en) | Antibody molecules to pd-l1 and uses thereof | |
| DK3074534T3 (da) | Fremgangsmåder til polynukleotidsekventering | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK2840593T3 (da) | Forbedret afbryderindretning og fremgangsmåde til fremstilling dertil | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| CL2016001212A1 (es) | Moduladores de aplnr y usos de estos | |
| IL240388A0 (en) | Methods of treating melanoma | |
| DK3087095T3 (da) | FcRn-antagonist og fremgangsmåder til anvendelse | |
| DK3009021T3 (da) | Handske og fremgangsmåde til fremstilling deraf | |
| HUE055465T2 (hu) | PD-L1 ellenes humán antitestek | |
| PL3039939T3 (pl) | Sposoby i aparatura łącza wstępującego dla wielu użytkowników | |
| DK3301447T3 (da) | Anti-tumorrespons til modificerede selvepitoper | |
| DK3079719T3 (da) | ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf | |
| EP2919168A4 (en) | PORTABLE ELECTRONIC DEVICE | |
| DK4032985T3 (da) | Mikropeptider og anvendelse deraf til at modulere genekspressionen | |
| EP2964120A4 (en) | ILIAKALVERBINDER | |
| DK3065771T3 (da) | Fremgangsmåder og sammensætninger til vedvarende immunterapi | |
| DK2657517T3 (da) | System og fremgangsmåde til vindmøllestyring | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| DK3078724T6 (da) | Fremgangsmåde til fremstilling af biodiesel og relaterede produkter |